Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishMedium impact
Esc

Agilent Stock Jumps 4.7% on Raised Full-Year Growth Guidance

Investing.com2 min read5 sources

Why is Agilent stock up today?

Agilent Technologies (A) stock rose 4.7% to $173 on Thursday after management raised full-year core growth guidance to 5.8-6% at the JPMorgan U.S. All Stars Conference.

Key numbers

1-Day Stock Move+4.7%to $173 close, new 52-week high
Q3 FY2026 Revenue$1.878B+8.1% vs. year ago; +7.3% core
Full-Year Revenue Guidance$7.49B–$7.51Bcore growth 5.8–6%, raised ~65 bps
FY2026 Non-GAAP EPS Guidance$6.18–$6.21raised at midpoint
China Revenue Growth Q3 (per [1])+9% reportedpharma double-digit; advanced materials high-teens
Non-GAAP Operating Margin (Q3)28.3%+320 bps vs. year ago

What happened

Agilent Technologies (A) stock rose 4.7% to $173 on Thursday after management raised full-year core growth guidance to 5.8-6% at the JPMorgan U.S. All Stars Conference. Agilent makes the testing and measurement tools used in pharmaceutical labs and chemistry research, and its China business came in far stronger than expected — pharma customers grew at a double-digit rate and advanced materials posted high-teens gains. The company now expects fiscal 2026 revenue of $7.49B–$7.51B, with non-GAAP earnings of $6.18–$6.21 per share. Management credited its multi-year Ignite transformation program for accelerating growth and lifting non-GAAP operating margins by more than three percentage points year over year.

Why it matters

Agilent Technologies is a broad gauge of spending on lab equipment across pharma and industrial research, so strong guidance signals health across those markets. China's rebound is especially significant — that market had been in a prolonged downturn since 2023, and a sustained recovery benefits the whole scientific-instruments sector. Investors are also watching whether the Ignite program can keep lifting margins, which rose more than three percentage points in the latest quarter.

Who this affects

Marketbullish
Medium impact
Life-sciences instrument stocks broadly higher on China rebound.
Companybullish
High impact
Guidance raise confirms Ignite turnaround is gaining momentum.
Competitorsmixed
Low impact
Waters, Danaher face renewed Agilent competition in pharma tools.
Industrybullish
Medium impact
China pharma recovery brightens global life-sciences instrument outlook.

Agilent vs Waters, Mettler-Toledo, Danaher

Agilent TechnologiesA$48.8B+4.7%+27%24x+8.1%
Waters CorporationWAT$42.4B+2.8%+13.5%27x+9% organic
Mettler-ToledoMTD$30.6B+2.4%+9.6%30x+4.5%
DanaherDHR$156.8B+0.8%-2.6%25x+5.5%

As of 2026-09-24

How we got here

  1. Agilent Q3 FY2026 results: $1.878B revenue, core +7.3%, guidance raised

  2. Agilent announces JPMorgan U.S. All Stars Conference participation

  3. Management presents at JPMorgan; cites 10-11% organic growth in top segments

  4. Stock jumps 4.7% to $173, reaching a new 52-week high

What to watch

  • Q4 FY2026 earnings; guidance calls for $1.98B–$2.00B revenueQ4 2026
  • China pharma order trends; any reversal could pressure full-year guidance2026-12-01
  • Ignite program milestones and further margin expansion updatesQ4 2026

Educational content only. Not investment advice.

More briefsAll briefs →